Your entry is only as good as your exit strategy...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
lovely...
ATTD... .0051 X .0052...700,000 pre market volume...
SATM...officially...GESI...the new ticker..
Good Morning...Enjoy and have a great day...
TGTX... .16...News.. outstanding.. 7,398,316...
TG Therapeutics Completes Licensing Agreement With LFB Biotechnologies for the Development of Ublituximab
8:30 AM ET 3/2/12 | GlobeNewswire
TG Therapeutics, Inc. - announced today an agreement with two LFB Group companies, LFB Biotechnologies S.A.S and GTC Biotherapeutics, Inc., to license the worldwide commercial rights to Ublituximab, a novel, third generation chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen found on B lymphocytes.
TG Therapeutics, Inc. also announced the closing of a capital raise, resulting in gross proceeds of approximately $25 million. Proceeds from the financing will be used primarily to fund the continued clinical development of Ublituximab and general corporate purposes. Additionally, concurrently with the license and financing, TG Therapeutics, Inc. became a majority-owned subsidiary of Manhattan Pharmaceuticals, Inc. (OTCBB:TGTX), which intends to change its name to TG Therapeutics, Inc. OPN Capital Markets acted as lead placement agent for this capital raise and as an exclusive financial advisor for the Exchange Transaction between Manhattan Pharmaceuticals, Inc. and TG Therapeutics, Inc.
Mr. Michael Weiss, Executive Chairman, Interim CEO and President stated, "We are very pleased to be able to close the financing and complete this licensing agreement with LFB Biotechnologies for Ublituximab. Ublituximab has displayed high single agent response rates in a Phase 1/2 clinical trial in patients with relapsed Chronic Lymphocytic Leukemia. We are eager to expand development of this novel therapeutic for various B-cell proliferative diseases."
"This agreement with TG Therapeutics is a real opportunity to develop and commercialize at a large scale a very promising therapeutic thanks to its high Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) activity based on a LFB Biotechnologies technological platform," said Christian Bechon, CEO of LFB S.A (holding company of LFB Group).
ABOUT UBLITUXIMAB
Ublituximab is a novel, third generation chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen found on B lymphocytes. Through LFB Biotechnologies' proprietary technology, Ublituximab has been bioengineered for enhanced biological activity with an increased ability to trigger an immune response, delivering superior ADCC effects to aid in B-cell depletion. Ublituximab has displayed high single agent activity in a Phase 1/2 clinical trial in patients with relapsed Chronic Lymphocytic Leukemia, and is being developed by TG Therapeutics in multiple oncology and autoimmune indications.
The recombinant anti CD 20 was granted orphan status in Europe and in the USA for B-cell Chronic Lymphocytic Leukemia.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is an innovative, clinical-stage biopharmaceutical company formed as a spinout from LFB Biotechnologies (minority stake) and focused on the development and commercialization of a novel, third generation anti-CD20 monoclonal antibody, Ublituximab, for the treatment of various B-cell proliferative disorders.
The TG Therapeutics logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11857
ABOUT LFB GROUP
LFB Group is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases. The LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide and is also among the leading European companies for the development of monoclonal antibodies and new-generation proteins based on biotechnologies. In 2010, the LFB Group reported total turnover of EURO411.6M, up 9.6%, and invested EURO86.5M in product development.
LFB Biotechnologies is a wholly owned subsidiary of LFB S.A. that focuses on the group's R&D and biotech activities in two core areas: monoclonal antibodies and technological innovations in biomanufacturing. GTC Biotherapeutics is a wholly-owned subsidiary of LFB Biotechnologies. GTC Biotherapeutics develops, supplies and commercializes therapeutic proteins produced through transgenic animal technology. ATryn(R), GTC's recombinant human antithrombin, has been approved for use in the United States and Europe.
The LFB Biotechnologies logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11858
Cautionary Statement
Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for ublituximab may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for Ublituximab; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data analyses from prior pre-clinical and clinical trials; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at -www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
(Logo: http://www.primezone.com/newsroom/prs/?pkgid=)
(Logo: http://www.primezone.com/newsroom/prs/?pkgid=)
Source: TGTX-G
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Manhattan Pharmaceuticals, Inc.
CONTACT: Jenna Bosco
Director- Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4484
Email: ir@tgtxinc.com
Sandrine Charrieres
Head of Communications
LFB GROUP
Telephone: +33 1.69.82.72.80
Email: charrieres@lfb.fr
QFOR... .40...outstanding..49,250,490...News...I am not posting a chart because as I research this company this is not a trade but a long term investment in a solid company...read the financials..it is a must...
March 2, 2012 - 8:30 AM EST
ROLLING MEADOWS, IL -- (Marketwire) -- 03/02/12 -- Quadrant 4 Systems Corporation (Quadrant) (OTCBB: QFOR) (OTCQB: QFOR) today announced that it has begun development of its cloud enabled comprehensive platform for the US national health insurance exchanges which will become operational in 2014.
The Affordable Care Act (ACA) of the United States seeks to increase insurance coverage for 32 million uninsured individuals, including 24 million who are expected to obtain coverage through a health insurance exchange according to a Congressional Budget Office projection. The number who might eventually obtain coverage through these exchanges may be up to 65 million if employers curtail employer-sponsored insurance programs or larger numbers of individuals pursue coverage.
ACA must be operational by 2014 and many States are in the final stages of requesting formal bids to develop, participate and/or operate these health exchanges per Federal guidelines. The significant part of these exchanges will be the core software platform that provides functionalities to qualify and enroll and process the individuals. Quadrant believes that it is a huge opportunity and has begun architecting and developing a cloud based platform that will have comprehensive set of functionalities that will satisfy the requirements of private health exchanges as well as exchanges being proposed by many US States. The platform will offer a complete set of functionalities and interfaces for Health Plan Administrator, Payers, and Health Care providers as well as groups and individuals looking to purchase insurance through the health insurance exchange market place.
Dr. Nandu Thondavadi, CEO of Quadrant, said, "Through this platform, Quadrant4's addressable market, just in exchange space for the software development opportunity alone, would run into at least $5 million per State, and every dollar spent on software development would lead into at least $5 in recurring managed services revenues. This will be a very substantial market for our company to be in, which should eventually make us a standout in the industry through our healthcare practice."
Dhru Desai, Chairman of Quadrant, commented, "There is a tremendous opportunity to introduce advanced Information Technology in healthcare infrastructure to help control costs while improving the quality of healthcare. Quadrant4's Health Insurance Exchange platform architecture is based on advanced technology stack that the company has been developing over last six months and represents a true convergence of Cloud Computing, Mobility Solutions and a Social Media based tool set. The platform envisions advanced analytics capabilities to monitor the cost and quality of healthcare."
About Quadrant 4 Systems Corporation
Quadrant 4 Systems Corporation delivers end-to-end information technology solutions to its clients through a unique blend of consulting, software development & maintenance, cloud based products and technology from its global delivery centers. The company currently focuses on Financial Services, Health Care, Retail, Manufacturing and Telecommunication sectors with a broad spectrum of services and technology practices that include ERP, SCM, CRM, e-Commerce, m-Commerce, SFA, Microsoft, Java and Legacy platforms, BI/DW, testing, platform migration, web technologies and others. The company plans to expand its offerings in the IT enabled managed services and cloud computing software products through internal development as well as through business acquisitions.
Forward-Looking Statements
This release contains forward-looking statements which are subject to the inherent uncertainties in predicting future results and conditions. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "anticipate," "expects," "estimates," and similar expressions) should be considered to be forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Exchange Act of 1934, as each is amended, for which the Private Securities Litigation Reform Act of 1995 provides a safe harbor. Certain factors (including but not limited to those risk factors identified from time to time in our filings with the Securities and Exchange Commission as well as changes in economic conditions; outcome of negotiations; changes in the Company's access to necessary capital; outcome of litigation; volatility of capital markets; variability and timing of business opportunities; changes in accounting policies and practices; the effects of internal organizational changes; adverse state and federal regulation and legislation; and the occurrence of extraordinary or catastrophic events and terrorist acts; or other unforeseen changes in circumstances) could cause actual results and conditions to differ materially from those projected in such forward-looking statements. We do not undertake any obligation to release publicly revised or updated forward-looking information, and such information included in this release is based on information currently available and may not be reliable after this date.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Investor Contact
BPC Financial Marketing
John Baldissera
800-368-1217
Source: Marketwire (March 2, 2012 - 8:30 AM EST)
News by QuoteMedia
VDSC...spread tightening up...
Now that's funny...
ATTD...News...
Attitude Drinks Announces Four New Distributors
Font size: A | A | A
1:54 PM ET 3/1/12 | PR Newswire
Attitude Drinks (OTC.BB: ATTD) (OTCQB: ATTD.OB - News) today announced that it has appointed several companies to distribute Phase III® Recovery Drink in their markets in the southeastern United States.
Birmingham Beverage Co (Birmingham, AL), Classic City Beverages (Athens, GA), Cone Distributing (Ocala, FL), and Ideal Distributing (Cookeville, TN) have ordered and received Phase III® Recovery and have commenced sales.
Jack Shea, Executive VP of Sales for Attitude, said:"We are extremely excited that we will be partnering with these strong distributors in the southeast. We are moving closer to our goal of having Phase III® available to consumers throughout the southeast region."
About Attitude Drinks Inc.
Attitude Drinks Inc. is an innovative, beverage brand development company with a focus on functional milk, ready-to-drink beverages. Phase III® is the Company's first, functional pure milk-based recovery drink that exploits recent scientific evidence confirming the benefits of milk and protein as an exercise recovery aid. Phase III is sold in select local, regional and national markets, including colleges, universities, convenience stores, fitness centers and gyms, as well as online. For more information, visit www.attitudedrinks.com.
This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.
Contact: Roy Warren, CEOAttitude Drinks, Inc.561.227.2727roy@attitudedrinks.com
SOURCE Attitude Drinks Inc.
MWWC.. .005 X .0055...heavy volume here..
Don't we all...
NVLX... .073 X .074
EFIR ...0036 X .0038...crazy..
Me too...
ASFX....OO1 X .0012...looking for .0009 entry...
MDRM...News...
Modern Mobility Aids, Inc. Announces a Revised Agreement for the Acquisition of Lumigene
Innovative healthcare products and delivery solutions to drive business growth
TORONTO, March 1, 2012 /PRNewswire/ -- Modern Mobility Aids, Inc. (the "Company"), headquartered in Nevada, USA (OTC: MDRM), has revised its agreement to acquire of all the common stock of Lumigene Technologies Inc. ("Lumigene") and expects to complete the transaction by March 31, 2012.
Lumigene is a private Canadian company engaged in developing molecular diagnostic products for the rapid and accurate detection of a number of specific pathogens and infectious diseases. With the acquisition of Lumigene, the Company will address the ever-increasing demand for less time-consuming and more cost-effective methods of DNA testing and diagnosis of infectious diseases at point of care. (Current testing methods typically require several day's work by highly trained technicians in an off-site laboratory.)
Mohamed K. Karatella, President and CEO, discussed the largely unmet need to speed up DNA sample preparation in order to obtain immediate and accurate results on site and the user friendly products being developed by Lumigene for this purpose. --- "Staff at hospitals, healthcare clinics and even airports need fast detection of pathogens, infectious diseases and other ailments right at the point of DNA sampling. Delivering the first available solution to produce such reliable results within an hour with Lumigene's automated and economic technology will open up a broad range of applications with a large global market potential. We are also very pleased to welcome Lumigene's highly talented technical team, which will greatly enhance our innovative bioscience research and add strength to our management team also."
Under the revised agreement, the purchase price for Lumigene is largely predicated on the achievement of certain key business, patent and technological milestones.
About Modern Mobility Aids, Inc.
investor@mdrmgroup.com
416 645 8350
SOURCE Modern Mobility Aids, Inc.
Source: PR Newswire (March 1, 2012 - 11:50 AM EST)
News by QuoteMedia
EFIR... .0034 X .0035...
EFIR.. .0031 X .0032.. 100 million volume..
AOGN... .0016 X.0017 ... ubss..on bid with 2.25 million...
MWIP...trying to break and hold 200 ma...that could take it to pennyland...imo..
yeah .....yeah.....monsta..
yeah....yeah....
EFIR... .003 X .0031
yup...
EFIR... .0028 X .0029...
we shall see..right now I am waiting for it to hit a penny..
EFIR.. .0026 X .0027
EFIR... .0025 X .0026..
EFIR... .0024 X .0025...
MWIP...News..
MediSwipe Inc. Completes Due Diligence Period and Announces Decision to Sign Definitive Agreement With ReachMeDaily.com
9:55 AM ET 3/1/12 | GlobeNewswire
MediSwipe Inc. (www.MediSwipe.com) (OTCBB:MWIP.OB), a merchant payment solutions and financial products company for the medical health care industry, today announced that the Company has completed the due diligence period and has decided to move forward with the signing of the Definitive Agreement with ReachMeDaily.com.
The Company initially announced the Letter of Intent with ReachMe Daily.com, (www.ReachMeDaily.com) the Florida based social media and HIPAA compliant platform which connects families with seniors residing in nursing homes and assisted living facilities on February 2, 2012. Through the ReachMeDaily agreement, MediSwipe will own the proprietary assets as a wholly owned subsidiary, and market the proprietary HIPAA compliant, private social media platform as a white label solution to nursing homes, hospitals and medical practices for the fastest growing segment of social media for people aged 50 and older. While Twitter, Foursquare and Facebook may be grabbing most of the social media headlines of the moment, alternatively, only old forms of social media like wikis continue to play a major role in online healthcare communities. The Definitive Agreement is expected to be signed by the month's end.
"From the moment we first identified this opportunity it was clearly an ideal fit with our goal of expanding into vertical markets within the healthcare sector. We would also like to inform our shareholders that we have completed the two year audit for our 800 Commerce division and expect to complete the S-1 filing initiating the spin-off of the division this month as well. We have several announcements forthcoming for the 800 Commerce division, and look forward to a well received response by our investors and existing shareholders," stated B. Michael Friedman, CEO, MediSwipe Inc.
DEFINITIVE AGREEMENT DETAILS
The Definitive Agreement outlines the incremental transfer of common stock which will carry current and appropriate legends in accordance with U.S. Securities laws. The Definitive Agreement also outlines cash commitments over the first year for initial and secondary project work in the approximate amount of $250,000 to complete further software development of the ReachMeDaily platform. Further details will be released within the Company's 8K once the definitive agreement is signed.
About MediSwipe Inc.
MediSwipe Inc. (www.MediSwipe.com) offers a full spectrum of secure and reliable transaction processing and security solutions for the medical and healthcare industries, using traditional, Internet Point-of-Sale (POS), e-commerce and mobile (wireless) payment solutions. The Company now also offers digitized personal health records in conjunction with Industry Alliance Partners. MediSwipe offers reliable merchant payment solutions and closed loop pre-paid stored value and loyalty cards as a unique cash alternative to these regulated and e-commerce businesses specializing within the healthcare sector.
About Reach Me Daily
Reach Me Daily (www.ReachMeDaily.com) brings social networking to families, seniors and residential centers. Nursing homes and assisted living facilities can now offer family members a way to stay connected with their loved one using social media. The Company has developed a HIPAA compliant, closed looped and secure application that can be private labeled to healthcare facilities worldwide.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of MediSwipe Inc. to be materially different from the statements made herein.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: MediSwipe Inc.
CONTACT: MediSwipe Inc.
Investor Relations:
615.252.4099
info@MediSwipe
NVLX... .07 X .073
EFIR.... .0019 X .0022
yeah...yeah....EFIR...
yes it is....needed a break...look at that volume..
EFIR...volume alert... ..0017 X .0018...
MWIP.. .0064 X .0065..
NVLX... .068 X .069
.0065 getting hammered...
MWIP...Nice dip here.. .0059 X .0060
NVLX...nice dip here... .062 X .065